EP Patent

EP2342198A1 — Salts of n-[6-cis-2,6-dimethylmorpholin-4yl)pyridine-3yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide

Assigned to Novartis AG · Expires 2011-07-13 · 15y expired

What this patent protects

Salts of N-[6-(cis-2,6-dimethylmorpholin-4-y)pyridine-3-yl]-2-methyl-4'- (trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide are prepared and characterized.

USPTO Abstract

Salts of N-[6-(cis-2,6-dimethylmorpholin-4-y)pyridine-3-yl]-2-methyl-4'- (trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide are prepared and characterized.

Drugs covered by this patent

sonidegib-phosphate (SONIDEGIB PHOSPHATE)

Patent Metadata

Patent number: EP2342198A1
Jurisdiction: EP
Classification: —
Expires: 2011-07-13
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.